Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Study Performed to Evaluate the Clinical Performance (Debridement), Safety and Pharmacology Effect of EscharEx (EX-02 Formulation) in Patients With Lower Leg Ulcers (VLU and DFU)

Next Previous
X
Search
Trial Profile

A Prospective Study Performed to Evaluate the Clinical Performance (Debridement), Safety and Pharmacology Effect of EscharEx (EX-02 Formulation) in Patients With Lower Leg Ulcers (VLU and DFU)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EscharEx (Primary)
  • Indications Diabetic foot ulcer; Leg ulcer; Varicose ulcer
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms Pharmex

    • Most Recent Events

    • 21 Dec 2023 According to MediWound media release, data from this study were published in the December 2023 issue of WOUNDS Journal.
    • 21 Dec 2023 Results published in a MediWound Media Release.
    • 26 Apr 2023 According to MediWound media release, results from this study will be presented at the 2023 Symposium on Advanced Wound Care (SAWC) Spring, Wound Healing Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top